Alan Michelson, MD

Alan Michelson, MD

Attending Physician; Director, Center for Platelet Research Studies; Director, Thrombosis and Anticoagulation Program

Professor of Pediatrics, Harvard Medical School

  • Contact: 617-919-2116; Dept: 617-355-8246

  • Fax: 617-730-0641

Medical Services

Specialties

  • Bleeding Disorders
  • Thrombosis
  • Platelet Disorders
  • Hematology Oncology

Departments

  • Hematology / Oncology
  • Medicine

Programs

  • Hematology / Oncology
  • Hematology / Oncology
  • Thrombosis and Anticoagulation Program
  • Rare Anemias and Iron Disorders Program
To schedule an appointment: Call 617-919-2116; Dept: 617-355-8246

Experience and Education

Education

Medical School

University of Adelaide, 1974

Adelaide, Australia

Internship

Alfred Hospital, 1974-1975

Melbourne, Australia

Pediatrics

Royal Children's Hospital, 1975-1976

Melbourne, Australia

Residency, Pediatrics

The Children's Hospital, 1976-1978

Sydney, Australia

Pediatric Hematology

The Children's Hospital, 1978-1982

Sydney, Australia

Publications

Publications powered by Harvard Catalyst
  1. Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 Jul 4; 116(1):69-77.
  2. Gremmel T, Frelinger AL, Michelson AD. Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204.
  3. Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9.
  4. Gremmel T, Michelson AD, Frelinger AL. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16.
  5. Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 1; 107:204-18.
  6. Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD, Fontana P, Reny JL, Frelinger AL. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016 May; 27(3):196-202.
  7. Gremmel T, Frelinger AL, Michelson AD. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599.
  8. Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78.
  9. Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9.
  10. Frelinger Iii AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Gerrits AJ, Carmichael SL, Neculaes VB, Michelson AD. Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016 Mar; 27(2):128-35.
  11. Show all
  12. Sakurai Y, Fitch-Tewfik JL, Qiu Y, Ahn B, Myers DR, Tran R, Fay ME, Ding L, Spearman PW, Michelson AD, Flaumenhaft R, Lam WA. Platelet geometry sensing spatially regulates a-granule secretion to enable matrix self-deposition. Blood. 2015 Jul 23; 126(4):531-8.
  13. McCrindle BW, Li JS, Manlhiot C, Tweddell JS, Giglia TM, Massicotte MP, Monagle P, Krishnamurthy R, Mahaffey KW, Michelson AD, Verdun N, Almond CS, Newburger JW, Brandão LR, Esmon CT, Manco-Johnson MJ, Ichord R, Ortel TL, Chan AK, Portman R, Rose M, Strony J, Kaltman JR. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation. 2014 Sep 30; 130(14):1192-203.
  14. Torres AS, Caiafa A, Garner AL, Klopman S, LaPlante N, Morton C, Conway K, Michelson AD, Frelinger AL, Neculaes VB. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100.
  15. Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8.
  16. Berny-Lang MA, Darling CE, Frelinger AL, Barnard MR, Smith CS, Michelson AD. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9.
  17. Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780.
  18. Darling CE, Sala Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, Michelson AD, Whittaker P, Welch RD, Przyklenk K. Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open. 2014; 4(1):e003883.
  19. Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014 Jan; 12(1):2-13.
  20. Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7.
  21. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85.
  22. Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 Jun; 2(3):e000026.
  23. Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3.
  24. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35.
  25. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9.
  26. Michelson AD. Gray platelet syndrome. Blood. 2013 Jan 10; 121(2):250.
  27. Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80.
  28. Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62.
  29. Peters CG, Michelson AD, Flaumenhaft R. Granule exocytosis is required for platelet spreading: differential sorting of a-granules expressing VAMP-7. Blood. 2012 Jul 5; 120(1):199-206.
  30. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3; 59(14):1304-11.
  31. Jennings LK, Michelson AD, Jacoski MV, Tyagi A, Grgurevich S, Li JS. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. Platelets. 2012; 23(6):430-8.
  32. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72.
  33. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8.
  34. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10.
  35. Scheer FA, Michelson AD, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549.
  36. Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26.
  37. Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger AL, Sola-Visner M. Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8.
  38. Rahangdale S, Yeh SY, Novack V, Stevenson K, Barnard MR, Furman MI, Frelinger AL, Michelson AD, Malhotra A. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8.
  39. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46.
  40. Trenor CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011 Feb; 127(2):347-57.
  41. Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011:62-9.
  42. Frelinger AL, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9.
  43. Trenor CC, Michelson AD. Thrombophilia and pediatric stroke. Circulation. 2010 Apr 27; 121(16):1795-7.
  44. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010 Feb; 9(2):154-69.
  45. Lajer M, Tarnow I, Michelson AD, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32.
  46. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96.
  47. Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65.
  48. Przyklenk K, Frelinger AL, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40.
  49. Tarnow I, Michelson AD, Barnard MR, Frelinger AL, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9.
  50. Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009 Sep; 16(5):371-7.
  51. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-97.
  52. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63.
  53. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009 Jun; 7(6):1029.
  54. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009 Feb 2; 103(3 Suppl):20A-26A.
  55. Bednarek FJ, Bean S, Barnard MR, Frelinger AL, Michelson AD. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5.
  56. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44.
  57. Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, Michelson AD, Kupferwasser LI, Xiong YQ, Bayer AS, Yeaman MR. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun. 2008 Dec; 76(12):5706-13.
  58. Darling CE, Michelson AD, Volturo GA, Przyklenk K. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. J Thromb Thrombolysis. 2009 Jul; 28(1):31-7.
  59. Monagle P, Chalmers E, Chan A, DeVeber G, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):887S-968S.
  60. Tarnow I, Kristensen AT, Krogh AK, Frelinger AL, Barnard MR, Michelson AD. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52.
  61. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
  62. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
  63. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
  64. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
  65. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
  66. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
  67. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
  68. Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation. 2008 Jan 29; 117(4):553-9.
  69. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s33-8.
  70. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32.
  71. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 Feb; 6(2):359-65.
  72. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007 Nov 6; 50(19):1822-34.
  73. Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98.
  74. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200.
  75. Tarnow I, Michelson AD, Frelinger AL, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP. Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62.
  76. Linden MD, Furman MI, Frelinger AL, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5.
  77. Harrison P, Frelinger AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36.
  78. Michelson AD. Arterial ischemic stroke in children: baby steps. Circulation. 2006 Nov 14; 114(20):2094-5.
  79. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N.
  80. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81.
  81. Linden MD, Whittaker P, Frelinger AL, Barnard MR, Michelson AD, Przyklenk K. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7.
  82. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006 Sep 1; 98(5):577-9.
  83. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96.
  84. Kereiakes DJ, Michelson AD. Platelet activation and progression to complications. Rev Cardiovasc Med. 2006; 7(2):75-81.
  85. Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb. 2006; 35(1-2):67-82.
  86. Wiviott SD, Michelson AD, Berger PB, Lepor NE, Kereiakes DJ. Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med. 2006; 7(4):214-25.
  87. Michelson AD. Aspirin resistance. Pathophysiol Haemost Thromb. 2006; 35(1-2):5-9.
  88. O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med. 2006 Mar 1; 173(5):483-90.
  89. Serebruany VL, Oshrine BR, Malinin AI, Atar D, Michelson AD, Ferguson JJ. Noncompliance in cardiovascular clinical trials. Am Heart J. 2005 Nov; 150(5):882-6.
  90. Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI, Michelson AD. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70.
  91. Frelinger AL, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7.
  92. Eikelboom J, Feldman M, Mehta SR, Michelson AD, Oates JA, Topol E. Aspirin resistance and its implications in clinical practice. MedGenMed. 2005; 7(3):76.
  93. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005 Jun; 3(6):1309-11.
  94. O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41.
  95. Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, Frelinger AL, Michelson AD. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005 Feb; 3(2):312-20.
  96. Israels SJ, Michelson AD. Antiplatelet therapy in children. Thromb Res. 2006; 118(1):75-83.
  97. Valeri CR, MacGregor H, Barnard MR, Summaria L, Michelson AD, Ragno G. Survival of baboon biotin-X-N-hydroxysuccinimide and (111)In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. Vox Sang. 2005 Feb; 88(2):122-9.
  98. Michelson AD. Platelet function testing in cardiovascular diseases. Hematology. 2005; 10 Suppl 1:132-7.
  99. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004 Nov 9; 110(19):e489-93.
  100. Valeri CR, Macgregor H, Barnard MR, Summaria L, Michelson AD, Ragno G. In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. Transfusion. 2004 Oct; 44(10):1505-12.
  101. Linden MD, Frelinger AL, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11.
  102. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):645S-687S.
  103. Furman MI, Frelinger AL, Michelson AD. GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis. 2004 Aug; 18(1):11-7.
  104. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25.
  105. Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 1; 92(9):1099-101.
  106. Israels SJ, Rand ML, Michelson AD. Neonatal platelet function. Semin Thromb Hemost. 2003 Aug; 29(4):363-72.
  107. Michelson AD. How platelets work: platelet function and dysfunction. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):7-12.
  108. Michelson AD. Platelet inhibitor therapy: mechanisms of action and clinical use. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):13-5.
  109. Alugupalli KR, Michelson AD, Joris I, Schwan TG, Hodivala-Dilke K, Hynes RO, Leong JM. Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. Blood. 2003 Oct 15; 102(8):2843-50.
  110. Barnard MR, Krueger LA, Frelinger AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003 May; Chapter 6:Unit 6.15.
  111. Claytor RB, Michelson AD, Li JM, Frelinger AL, Rohrer MJ, Garnette CS, Barnard MR, Krueger LA, Furman MI. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5.
  112. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6.
  113. Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray PF. Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J Thromb Haemost. 2003 Feb; 1(2):355-62.
  114. Mitchell WB, Li JH, Singh F, Michelson AD, Bussel J, Coller BS, French DL. Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis. Blood. 2003 Mar 15; 101(6):2268-76.
  115. Rohrer MJ, Claytor RB, Garnette CS, Powell CC, Barnard MR, Furman MI, Michelson AD. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. Cardiovasc Surg. 2002 Oct; 10(5):464-9.
  116. Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5.
  117. Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 2002 Apr; 143(4):602-11.
  118. Krueger LA, Barnard MR, Frelinger AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. Curr Protoc Cytom. 2002 Feb; Chapter 6:Unit 6.10.
  119. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8.
  120. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6.
  121. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001 Sep 25; 104(13):1533-7.
  122. Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9.
  123. Gardiner EE, De Luca M, McNally T, Michelson AD, Andrews RK, Berndt MC. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood. 2001 Sep 1; 98(5):1440-7.
  124. Alugupalli KR, Michelson AD, Barnard MR, Leong JM. Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost. 2001 Aug; 86(2):668-71.
  125. Claytor RB, Li JM, Furman MI, Garnette CS, Rohrer MJ, Barnard MR, Krueger LA, Frelinger AL, Michelson AD. Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 1; 43(4):308-13.
  126. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 2001 Jan; 119(1 Suppl):344S-370S.
  127. Alugupalli KR, Michelson AD, Barnard MR, Robbins D, Coburn J, Baker EK, Ginsberg MH, Schwan TG, Leong JM. Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation. Mol Microbiol. 2001 Jan; 39(2):330-40.
  128. Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Barnard MR, Ofosu FA, Michelson AD. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost. 2000 Nov; 84(5):897-903.
  129. Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost. 2000 Oct; 84(4):689-94.
  130. Furman MI, Frelinger III AL, Michelson AD. Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. Curr Cardiol Rep. 2000 Sep; 2(5):386-94.
  131. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8.
  132. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70.
  133. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000 Mar 7; 101(9):1013-8.
  134. Michelson AD. Flow cytometric analysis of platelets. Vox Sang. 2000; 78 Suppl 2:137-42.
  135. Loscalzo J, Freedman J, Inbal A, Keaney JF, Michelson AD, Vita JA. Nitric oxide insufficiency and arterial thrombosis. Trans Am Clin Climatol Assoc. 2000; 111:158-63.
  136. Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman MI, Michelson AD. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg. 1999 Nov; 30(5):844-51.
  137. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999 Sep; 6(5):342-8.
  138. Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, Michelson A, Trolliet M, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999 Aug; 19(8):2017-23.
  139. Barnard MR, MacGregor H, Ragno G, Pivacek LE, Khuri SF, Michelson AD, Valeri CR. Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity. Transfusion. 1999 Aug; 39(8):880-8.
  140. Barnard MR, MacGregor H, Mercier R, Ragno G, Pivacek LE, Hechtman HB, Michelson AD, Valeri CR. Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis. Transfusion. 1999 Jul; 39(7):735-41.
  141. Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem. 1999 May 14; 274(20):14368-75.
  142. Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, Michelson AD, Gagnon DR, Valeri CR. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999 Jan; 117(1):172-83; discussion 183-4.
  143. Michelson AD, Barnard MR, Khuri SF, Rohrer MJ, MacGregor H, Valeri CR. The effects of aspirin and hypothermia on platelet function in vivo. Br J Haematol. 1999 Jan; 104(1):64-8.
  144. Michelson AD, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest. 1998 Nov; 114(5 Suppl):748S-769S.
  145. Himmelfarb J, Nelson S, McMonagle E, Holbrook D, Benoit SE, Michelson AD, Ault K. Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. Am J Kidney Dis. 1998 Jul; 32(1):132-8.
  146. Peyton BD, Rohrer MJ, Furman MI, Barnard MR, Rodino LJ, Benoit SE, Hechtman HB, Valeri CR, Michelson AD. Patients with venous stasis ulceration have increased monocyte-platelet aggregation. J Vasc Surg. 1998 Jun; 27(6):1109-15; discussion 1115-6.
  147. Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey TV. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998 May; 79(5):885-96.
  148. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr. 1998 Apr; 132(4):575-88.
  149. Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, Michelson AD. The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3082-7.
  150. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998 Feb; 31(2):352-8.
  151. Michelson AD. Platelet function in the newborn. Semin Thromb Hemost. 1998; 24(6):507-12.
  152. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997 Jul 15; 100(2):350-6.
  153. Rajasekhar D, Barnard MR, Bednarek FJ, Michelson AD. Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost. 1997 May; 77(5):1002-7.
  154. Michelson AD. Flow cytometric assessment of glycoprotein movements in platelets. Platelets. 1997; 8(2-3):105-15.
  155. Andrew M, Michelson AD, Bovill T, Leaker M, Massicotte P, Marzinotto V, Brooker LA. The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):7-22.
  156. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11877-82.
  157. Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 1996 Oct; 112(4):1098-107.
  158. Grabowski EF, Jang IK, Gold H, Head C, Benoit SE, Michelson AD. Variability of platelet degranulation by different contrast media. Acad Radiol. 1996 Sep; 3 Suppl 3:S485-7.
  159. Grabowski EF, Boor SE, Rodino LJ, Jang IK, Gold H, Michelson AD. Platelets are degranulated by some, but not all, contrast media. Acad Radiol. 1996 Aug; 3 Suppl 2:S328-30.
  160. Upchurch GR, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H, Ragno G, Francis S, Rodino LJ, Michelson AD, Loscalzo J. Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol. 1996 Aug; 271(2 Pt 2):H528-34.
  161. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996 Jun 15; 87(12):4925-36.
  162. Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol. 1996 May; 270(5 Pt 2):H1640-8.
  163. Li JM, Podolsky RS, Rohrer MJ, Cutler BS, Massie MT, Barnard MR, Michelson AD. Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. J Surg Res. 1996 Mar; 61(2):543-8.
  164. Michelson AD, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT. The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood. 1996 Feb 15; 87(4):1396-408.
  165. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996 Feb 15; 97(4):979-87.
  166. Barnard MR, Michelson AD. Images in clinical medicine. A morphologic question. N Engl J Med. 1995 Oct 19; 333(16):1051.
  167. Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 1995 Oct; 108(4 Suppl):506S-522S.
  168. Kamat SG, Michelson AD, Benoit SE, Moake JL, Rajasekhar D, Hellums JD, Kroll MH, Schafer AI. Fibrinolysis inhibits shear stress-induced platelet aggregation. Circulation. 1995 Sep 15; 92(6):1399-407.
  169. Grabowski EF, Jang IK, Gold H, Palacios IF, Boor SE, Rodino LJ, Michelson AD. Platelet degranulation induced by some contrast media is independent of their nonionic vs ionic nature. Acta Radiol Suppl. 1995; 399:182-4.
  170. Michelson A, Schuster B, Thias S, Haid CT. [Vestibular lesion in sudden deafness: a prognostic criterium for therapeutic success]. Laryngorhinootologie. 1995 Jan; 74(1):7-12.
  171. Rajasekhar D, Kestin AS, Bednarek FJ, Ellis PA, Barnard MR, Michelson AD. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost. 1994 Dec; 72(6):957-63.
  172. Michelson AD, Wencel-Drake JD, Kestin AS, Barnard MR. Platelet activation results in a redistribution of glycoprotein IV (CD36). Arterioscler Thromb. 1994 Jul; 14(7):1193-201.
  173. LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, Michelson AD. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood. 1994 Jul 1; 84(1):158-68.
  174. Michelson AD, Benoit SE, Kroll MH, Li JM, Rohrer MJ, Kestin AS, Barnard MR. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood. 1994 Jun 15; 83(12):3562-73.
  175. Grabowski EF, Head C, Michail HA, Jang IK, Gold H, Benoit SE, Michelson AD. Effects of contrast media on platelet activation using flowing whole blood aggregometry and flow cytometry of platelet membrane glycoproteins. Invest Radiol. 1994 Jun; 29 Suppl 2:S198-200.
  176. Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994 May; 71(5):633-40.
  177. LaRosa CA, Rohrer MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg. 1994 Feb; 19(2):306-18; discussion 318-9.
  178. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis. 1994 Feb; 5(1):121-31.
  179. Orchard MA, Goodchild CS, Prentice CR, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michelson AD. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 1993 Nov; 85(3):533-41.
  180. Grabowski EF, Head C, Michelson AD. Nonionic contrast media. Procoagulants or clotting innocents? Invest Radiol. 1993 Nov; 28 Suppl 5:S21-4.
  181. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD. Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993 Oct; 88(4 Pt 1):1502-11.
  182. Rohrer MJ, Kestin AS, Ellis PA, Barnard MR, Rodino L, Breckwoldt WL, Li JM, Michelson AD. High-dose heparin suppresses platelet alpha granule secretion. J Vasc Surg. 1992 Jun; 15(6):1000-8; discussion 1008-9.
  183. Michelson AD. Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. Semin Thromb Hemost. 1992 Jan; 18(1):18-27.
  184. Michelson AD. Thrombocytopenia associated with environmental exposure to polyurethane. Am J Hematol. 1991 Oct; 38(2):145-6.
  185. Matic GB, Jaspers SR, Miller TB, Michelson AD. Platelet glycogen synthase: further characterization and effect of insulin. Thromb Res. 1991 Aug 15; 63(4):427-32.
  186. Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, Michelson AD. Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood. 1991 Apr 15; 77(8):1740-8.
  187. Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991 Feb 15; 77(4):770-9.
  188. Michelson AD, Gore JM, Rybak ME, Cola CA, Barnard MR. Effect of in vivo infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib. Thromb Res. 1990 Dec 1; 60(5):421-4.
  189. Michelson AD, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood. 1990 Nov 15; 76(10):2005-10.
  190. Hosemann W, Michelson A, Weindler J, Mang H, Wigand ME. [The effect of endonasal paranasal sinus surgery on lung function of patients with bronchial asthma]. Laryngorhinootologie. 1990 Oct; 69(10):521-6.
  191. Burke MC, Bernhard JD, Michelson AD. Chemotherapy-induced painful acral erythema in childhood: Burgdorf's reaction. Am J Pediatr Hematol Oncol. 1989; 11(1):44-5.
  192. Michelson AD, Adelman B, Barnard MR, Carroll E, Handin RI. Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest. 1988 Jun; 81(6):1734-40.
  193. Michelson AD, Barnard MR. Thrombin-induced changes in platelet membrane glycoproteins. Prog Clin Biol Res. 1988; 283:159-62.
  194. Michelson AD. Flow cytometric detection of distinct subpopulations of platelets in individual patients. Prog Clin Biol Res. 1988; 283:131-6.
  195. Michelson AD, Barnard MR. Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood. 1987 Nov; 70(5):1673-8.
  196. Michelson AD. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med. 1987 Sep; 110(3):346-54.
  197. Michelson AD, Marshall PC. Transient neurological disorder associated with transient erythroblastopenia of childhood. Am J Pediatr Hematol Oncol. 1987; 9(2):161-3.
  198. Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood. 1986 Dec; 68(6):1280-4.
  199. Michelson AD, Loscalzo J, Melnick B, Coller BS, Handin RI. Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood. 1986 Jan; 67(1):19-26.
  200. Adelman B, Michelson AD, Handin RI, Ault KA. Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood. 1985 Aug; 66(2):423-7.
  201. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985 Jan; 65(1):32-40.
  202. Michelson AD, Lammi AT. Haemolytic anaemia associated with acquired toxoplasmosis. Aust Paediatr J. 1984 Nov; 20(4):333-5.
  203. Michelson AD. Inheritance of Diamond-Blackfan anemia. Med J Aust. 1982 Oct 30; 2(9):409-10.
To schedule an appointment: Call 617-919-2116; Dept: 617-355-8246

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close